Currency In USD
| Previous Close | 2.32 |
| Open | 2.31 |
| Day High | 2.32 |
| Day Low | 2.27 |
| 52-Week High | 2.68 |
| 52-Week Low | 1.03 |
| Volume | 2.68M |
| Average Volume | 3.29M |
| Market Cap | 1.02B |
| PE | -16.06 |
| EPS | -0.14 |
| Moving Average 50 Days | 2.31 |
| Moving Average 200 Days | 1.76 |
| Change | -0.03 |
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
GlobeNewswire Inc.
Mar 11, 2026 12:00 PM GMT
Post hoc data analysis concluded that sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, improved glycemic control after one year in patients with normal and mildly reduced kidney functionTHE WOODLANDS, Texas, March 11, 2026 (GLOBE NEWSWIRE) -- Lexico
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences
GlobeNewswire Inc.
Mar 03, 2026 9:01 PM GMT
THE WOODLANDS, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in an upcoming fireside chat at the 2026 Leerink Partners Global Healthcare Conference in
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
GlobeNewswire Inc.
Feb 26, 2026 1:30 PM GMT
THE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, March 5, 2026, prior to market open. Management wil